The Bird trial is a Belgian Real-world study where 334 patients with Chronic lymphocytic leukemia, Mantle Cell lymphoma or Waldenstrom Macroglobulinemia are being treated with Ibrutinib.
The last patient was recruited in January 2020 and patients will be followed up for 5 years.
The third interim analysis of the study with a median Follow up of 35 months, confirms that the sustained efficacy of ibrutinib in CLL and MCL in the real-world setting is similar to the efficacy seen in previous randomized controlled trials. No new safety concerns were observed.
The end of the study is predicted in 2025 but the results of the third interim analysis were already published as a poster presented during EHA Congress 2021.
Ine Durieux, Medical Science Liaison for Belgium had some questions for Prof. Ann Janssens from UZ Leuven, who is the coordinating investigator for this study. We are eager to hear about her experience with the once daily Ibrutinib during this podcast.